B-Type Natriuretic Peptide, Plasma
Use
B-type natriuretic peptide (BNP) is essential for diagnosing congestive heart failure (CHF). It is a 32-amino acid peptide secreted by the heart, primarily from the ventricles, in response to volume expansion and pressure overload. The BNP concentration increases with the severity of CHF and is loosely correlated with the New York Heart Association (NYHA) functional class. Elevated BNP levels may also occur in conditions like right heart failure, pulmonary hypertension, and acute coronary syndromes. It plays a role in regulating blood pressure and fluid balance through its natriuretic and diuretic properties.
Special Instructions
Not provided.
Limitations
Lack of elevation in BNP levels can be observed in very acute CHF cases or when ventricular inflow obstruction is present. Additionally, interference in assay results may occur due to circulating anti-animal antibodies in some patients who have been exposed to animal antigens.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Immunoenzymatic Assay)
Biomarkers
B-Type Natriuretic Peptide (BNP)
Protein
LOINC Codes
- 30934-4 - BNP SerPl-mCnc
- 30934-4 - BNP SerPl-mCnc
Result Turnaround Time
2-3 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.4 mL
Container
Lavender top (EDTA); Plastic vial
Collection Instructions
Centrifuge and aliquot plasma into plastic vial. Freeze immediately or within 7 hours of collection.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 365 days |